Abstract:Background: Sepsis is a life-threatening complication of an infection and remains one of the leading causes of mortality in surgical patients. Bacteremia induces excessive inflammatory responses that result in multiple organ damage. Chronic helminth infection and helminth-derived materials have been found to immunomodulate host immune system to reduce inflammation against some allergic or inflammatory diseases. Schistosoma japonicum cystatin (Sj-Cys) is a cysteine protease inhibitor that induces regulatory T-cells and a potential immunomodulatory. The effect of Sj-Cys on reducing sepsis inflammation and mortality was investigated. Methods: Sepsis was induced in BALB/c mice using cecal ligation and puncture (CLP), followed by intraperitoneal injection of different doses (10, 25 or 50 μg) of recombinant Sj-Cys (rSj-Cys). The therapeutic effect of rSj-Cys on sepsis was evaluated by observing the survival rates of mice for 96 h after CLP and the pathological injury of liver, kidney and lung by measuring the levels of alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and creatinine (Cr) in sera and the tissue sections pathology, and the expression of MyD88 in liver, kidney and lung tissues. The immunological mechanism was investigated by examining pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and IL-10 and TGF-β1 in mice sera and in culture of macrophages stimulated by lipopolysaccharides (LPS). Results: rSj-Cys treatment provided significant therapeutic effects on CLP-induced sepsis in mice demonstrated with increased survival rates, alleviated overall disease severity and tissue injury of liver, kidney and lung. The rSj-Cys conferred therapeutic efficacy was associated with upregualted IL-10 and TGF-β1 cytokines and reduced pro-inflammatory cytokines TNF-α, IL-6, IL-1β. MyD88 expression in liver, kidney and lung tissues of rSj-Cys-treated mice was reduced. In vitro assay with macrophages also showed that rSj-Cys inhibited the release of pro-inflammatory cytokines and mediator nitric oxide (NO) after being stimulated by lipopolysaccharide (LPS). Conclusions: The results suggest the anti-inflammatory potential of rSj-Cys as a promising therapeutic agent on sepsis. The immunological mechanism underlying its therapeutic effect may involve the downregulation of pro-inflammatory cytokines and upregulation of IL-10 and TGF-β1 cytokines possibly via downregulation of the TLR adaptor-transducer MyD88 pathway. The findings suggest rSj-Cys is a potential therapeutic agent for sepsis and other inflammatory diseases.

Recombinant protein Schistosoma japonicum -derived molecule attenuates dextran sulfate sodium-induced colitis by inhibiting miRNA-217-5p to alleviate apoptosis

rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-α Signaling Pathway.

Effects of a Recombinant Schistosomal-Derived Anti-Inflammatory Molecular (rsj16) on the Lipopolysaccharide (Lps)-Induced Activated RAW264.7.

Recombinant Sj16 Protein with Novel Activity Alleviates Hepatic Granulomatous Inflammation and Fibrosis Induced by Schistosoma Japonicum Associated with M2 Macrophages in a Mouse Model

Schistosoma Japonicum Attenuates Dextran Sodium Sulfate-Induced Colitis in Mice Via Reduction of Endoplasmic Reticulum Stress

Therapeutic Potential of Recombinant Cystatin from Schistosoma Japonicum in TNBS-induced Experimental Colitis of Mice.

Molecular cloning and expression of a functional anti-inflammatory protein, Sj16, of Schistosoma japonicum

Protective effect of Schistosoma japonicum eggs on TNBS-induced colitis is associated with regulating Treg/Th17 balance and reprogramming glycolipid metabolism in mice

A Recombined Protein (rsj16) Derived from Schistosoma Japonicum Induces Cell Cycle Arrest and Apoptosis of Murine Myeloid Leukemia Cells

[Studies on Immunomodulation Effect of Recombinant Sj16 from Schistosoma Japonicum on Inflammation Response of Host].

An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis

Rsj16, A Recombinant Protein of Schistosoma Japonicum-Derived Molecule, Reduces Severity of the Complete Freund'S Adjuvant-Induced Adjuvant Arthritis in Rats' Model

Suppression of Adaptive Immunity to Heterologous Antigens by SJ16 of Schistosoma Japonicum

Monosexual Cercariae of Schistosoma japonicum Infection Protects Against DSS-Induced Colitis by Shifting the Th1/Th2 Balance and Modulating the Gut Microbiota

Therapeutic effect of Schistosoma japonicum cystatin on bacterial sepsis in mice

Gene Expression Profile of Lps-Stimulated Dendritic Cells Induced by A Recombinant Sj16 (rsj16) Derived from Schistosoma Japonicum

Schistosoma japonicum IAP and Teg20 safeguard tegumental integrity by inhibiting cellular apoptosis.

Effect of Cystatin from Schistosoma Japonicum on DSS-induced Ulcerative Colitis in Mice

Retracted: MicroRNA‐29b‐3p Prevents Schistosoma Japonicum‐induced Liver Fibrosis by Targeting COL1A1 and COL3A1

Recombinant Sj16 from Schistosoma Japonicum Contains a Functional N-terminal Nuclear Localization Signal Necessary for Nuclear Translocation in Dendritic Cells and Interleukin-10 Production

Induction of hepatic fibrosis in mice with schistosomiasis by extracellular microRNA-30 derived from Schistosoma japonicum eggs